Alzheimer's disease is the most common form of dementia. Patients living with Alzheimer's experience a decline in memory, reasoning and the ability to perform routine daily activities. This disease has an impact, not only on those who suffer from it, but also families and caregivers who often experience great physical, emotional and economic stress.
It is currently estimated that more than 35 million people worldwide suffer from Alzheimer's, a figure that continues to grow. According to the World Health Organization, 82 million people could suffer from dementia by 2030 and that number could rise to 152 million by 2050, with Alzheimer's disease contributing to 60-70% of cases.
The AMBAR hypothesis
AMBAR is an innovative clinical trial aimed at slowing down the progression of Alzheimer's disease through periodic therapeutic plasma exchange.
AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain, and the Alzheimer Disease Research Center in Pittsburgh, PA, USA.
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?